MedTrace Logo

Oat and Cholesterol

NCT03911427 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2020-03-23

No results posted yet for this study

Summary

The primary objective is to assess the effect of an oat ingredient provided over 4 weeks on serum LDL cholesterol in men and women with elevated LDL-cholesterol compared to a placebo.

Secondary endpoints are fasting serum total- and HDL-cholesterol, non-HDL-cholesterol, triglycerides, glucose, insulin, glycated albumin, HOMA-IR and Framingham risk score

Conditions

  • Elevated LDL Cholesterol

Interventions

OTHER

Active oat beverage

Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month

OTHER

Control rice beverage

Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month

Sponsors & Collaborators

  • Glycemic Index Laboratories, Inc

    collaborator INDUSTRY

  • PepsiCo Global R&D

    lead INDUSTRY

Principal Investigators

  • Thomas MS Wolever, MD, PhD · Glycemic Index Laboratories, Inc

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2020-02-20
Completion
2020-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03911427 on ClinicalTrials.gov